

MERCURY LABORATORIES LIMITED

Date: August 09, 2022

To,
Listing Compliance Department
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Tower, 25th Floor
Dalal Street,
Mumbai – 400 001

Respected Sir,

Subject: Unaudited Quarterly Financial Results for the Quarter ended on June 30, 2022
Scrip Code: 538964

We are pleased to forward herewith Unaudited Financial Results of the Company for the quarter ended on June 30, 2022 along with limited review report of Auditor in compliance with the requirement of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The said financial results have been approved by Board of Directors at their meeting held on August 09, 2022.


We are also arranging to publish the same in newspaper in accordance with provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are therefore requested to take the above information on records.

Thanking You.

Yours faithfully,

FOR MERCURY LABORATORIES LIMITED


RAJENDRA SHAH
MANAGING DIRECTOR
DIN 00257253



Encl: As above


MERCURY LABORATORIES LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH JUNE 2022

| Sr.No. | Particulars | (Rs.in Lacs) | | | |
|--------|--|--------------------|-----------------|---------------------|-----------------|
| | | THREE MONTHS ENDED | | TWELVE MONTHS ENDED | |
| | | 30.06.2022 | 31.03.2022 | 30.06.2021 | 31.03.2022 |
| | | UNAUDITED | AUDITED | UNAUDITED | AUDITED |
| 1 | Revenue From Operations | 1,759.90 | 1,333.28 | 1,552.32 | 5,792.38 |
| 2 | Other Income | 49.18 | 36.55 | 12.94 | 81.59 |
| 3 | Total Income (1 + 2) | 1,809.08 | 1,369.83 | 1,565.26 | 5,873.97 |
| | EXPENSES | | | | |
| | a. Cost of materials consumed | 690.21 | 500.71 | 629.66 | 2,183.36 |
| | b. Purchase of Stock in Trade | 49.81 | 72.49 | 74.45 | 204.59 |
| | c. Changes in inventories of finished goods, work in progress and stock in | (8.34) | (21.92) | (72.17) | (22.00) |
| | d. Employee benefits expense | 348.80 | 351.86 | 298.23 | 1,237.30 |
| | e. Finance Costs | 9.43 | 4.03 | 10.97 | 44.64 |
| | f. Depreciation and Amortisation expenses | 61.47 | 61.74 | 50.99 | 245.28 |
| | g. Other Expenses | 452.62 | 291.37 | 393.92 | 1,477.68 |
| 4 | Total Expenses | 1,604.00 | 1,260.28 | 1,386.05 | 5,370.85 |
| 5 | Profit before exceptional and extraordinary items and tax (3- 4) | 205.08 | 109.55 | 179.21 | 503.12 |
| 6 | Exceptional Items | | | | |
| 7 | Profit before extraordinary items and tax (5-6) | 205.08 | 109.55 | 179.21 | 503.12 |
| 8 | Extraordinary Items | | | | |
| | a. Prior Period Tax Adjstment | | (12.75) | | (12.75) |
| 9 | Profit before tax (7- 8) | 205.08 | 122.30 | 179.21 | 515.87 |
| | Tax Expenses | | | | |
| | (1) Current Tax | 68.04 | 32.19 | 48.35 | 137.00 |
| | (2) Deferred tax | (9.28) | (5.46) | 6.25 | 10.25 |
| 10 | Total Tax Expenses | 58.76 | 26.73 | 54.60 | 147.25 |
| 11 | Net Profit after Tax (9- 10) | 146.32 | 95.57 | 124.61 | 368.62 |
| 12 | Other Comprehensive Income | | | | |
| | Items that will not be reclassified to profit or loss (Net of Tax) | | | | |
| | Items that will be reclassified to profit or loss (Net of Tax) | | | | |
| 13 | Total Other Comprehensive Income | | | | |
| 14 | Total Comprehensive Income | 146.32 | 95.57 | 124.61 | 368.62 |
| 15 | Paid up equity share capital (face value of Rs.10/- each) | 120.00 | 120.00 | 120.00 | 120.00 |
| 16 | Other Equity | | | | 3,914.08 |
| 17 | Earning Per Share (EPS) (not annualised) | | | | |
| | a) Basic Earning Per Share (* not annualised) | * 12.19 | * 7.96 | * 10.38 | 30.72 |
| | b) Diluted Earning Per Share (* not annualised) | * 12.19 | * 7.96 | * 10.38 | 30.72 |

Place : Vadodara
Date : 09.08.2022

For Mercury Laboratories Limited


Rajendra R. Shah
Managing Director
DIN: 00257253

Head Office & Factory - 1 :
2/13-14, Gorwa Industrial Estate, Gorwa,
Vadodara - 390 016, Ph. : 0265 2280180.
E-mail : mllbrd@mercurylabs.com

Factory - 2 :
Halol- Vadodara Road, Vill. : Jarod,
Vadodara - 391 510. Ph. : 02668 274312.


Regd. Office :
1st Floor 18, Shreeji Bhuvan, 51, Mangaldas Road,
Princess Street, Mumbai - 400 002. Ph. : 022 66372841
Fax : 022 2201 5441. E-mail : secretarial@mercurylabs.com

MERCURY LABORATORIES LIMITED

1. The above results were reviewed by the Audit Committee and have been approved by Board of Directors at their respective meetings held on 9th August 2022
2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms with Regulation 33 of SEBI (LODR), 2015 and SEBI Circular dated 05.07.2016.
3. The business of the Company fall under Single Segment i.e. "Pharmaceuticals Products".
4. Previous quarter's figure have been re grouped / re classified, wherever necessary to confirm to current period classification.

By order of the Board of Directors
For **MERCURY LABORATORIES LIMITED**

Place : Vadodara
Date : 9th August, 2022


RAJENDRA R SHAH
MANAGING DIRECTOR
DIN: 00257253



Dedicated to Mother & Child Healthcare

r. j. shah & associates
chartered accountants

R. J. Shah FCA
N. R. Dholakia FCA

D-408, Fifth Floor, Avishkar Complex, Old Padra Road, Vadodra-390 015
T: (O) 232 68 65 • e-mail: rjshahassociates@yahoo.com

Limited Review Report on the Unaudited Standalone Financial Results for the quarter ended June 30, 2022 pursuant to the Regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015.

To,
The Board of Directors,
Mercury Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Mercury Laboratories Limited (" the Company") for the quarter ended June 30, 2022 (" the Statement"), being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standard and other recognized accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Vadodara
Date : 9th August, 2022

For R. J. Shah & Associates
Chartered Accountants
FRN: 109752W

Nayan R Dholakia
Partner
M. No. 037350

UDIN: 22037350AORNAQ7672